The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.

Por Wright, J D, Helsby, N A, Ward, S A
Publicado em 1995

The multiple dose pharmacokinetics of proguanil.

Por Helsby, N A, Edwards, G, Breckenridge, A M, Ward, S A
Publicado em 1993

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

Por Helsby, N A, Ward, S A, Howells, R E, Breckenridge, A M
Publicado em 1990

The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.

Por Helsby, N A, Ward, S A, Edwards, G, Howells, R E, Breckenridge, A M
Publicado em 1990

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

Por Helsby, N A, Ferry, D M, Patterson, A V, Pullen, S M, Wilson, W R
Publicado em 2004

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Por Ward, S A, Helsby, N A, Skjelbo, E, Brøsen, K, Gram, L F, Breckenridge, A M
Publicado em 1991

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype

Por Helsby, N A, Lo, W-Y, Sharples, K, Riley, G, Murray, M, Spells, K, Dzhelai, M, Simpson, A, Findlay, M
Publicado em 2008